Balaxi Pharmaceuticals Limited (NSE:BALAXI)
32.30
-1.80 (-5.28%)
Dec 8, 2025, 1:40 PM IST
Balaxi Pharmaceuticals Revenue
Balaxi Pharmaceuticals had revenue of 561.75M INR in the quarter ending September 30, 2025, a decrease of -27.41%. This brings the company's revenue in the last twelve months to 2.76B, up 4.88% year-over-year. In the fiscal year ending March 31, 2025, Balaxi Pharmaceuticals had annual revenue of 2.93B with 21.25% growth.
Revenue (ttm)
2.76B
Revenue Growth
+4.88%
P/S Ratio
0.68
Revenue / Employee
4.61M
Employees
600
Market Cap
1.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 2.93B | 512.67M | 21.25% |
| Mar 31, 2024 | 2.41B | -951.38M | -28.28% |
| Mar 31, 2023 | 3.36B | 570.45M | 20.42% |
| Mar 31, 2022 | 2.79B | 480.55M | 20.77% |
| Mar 31, 2021 | 2.31B | 1.86B | 406.95% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |